Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

[Laryngo-Tracheal Resection as an Alternative to Permanent Tracheostomy].

Pneumologie (Stuttgart, Germany)·2019

Same author

[Diagnosis and Treatment of Diaphragmatic Dysfunction].

Pneumologie (Stuttgart, Germany)·2016

Same author

[Review of the Literature for Interpretation of Endobronchial Wound Healing after Tracheobronchial Sleeve Resection].

Pneumologie (Stuttgart, Germany)·2015

Same author

[Reduction of Tracheotomy Associated Tracheal Stenosis by Surgical Closure of the Tracheostomy].

Pneumologie (Stuttgart, Germany)·2015

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

Same journal

Der Internist·2024

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 7, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

[Multimodality therapy for lung cancer].

E Stoelben¹, R M Huber, R-P Müller

¹Lungenklinik Köln Merheim, Kliniken der Stadt Köln gGmbH, Ostmerheimerstraße 200, 51109, Köln. StoelbenE@kliniken-koeln.de

|October 23, 2010

Summary

This summary is machine-generated.

Lung cancer treatment varies by stage, with surgery, chemotherapy, and radiation therapy options. Personalized approaches targeting specific genetic alterations show recent progress for advanced lung cancer.

Related Experiment Videos

Last Updated: Jun 7, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Area of Science:

Oncology
Thoracic Surgery
Medical Oncology

Context:

Lung cancer treatment is highly dependent on the clinical stage of the tumor.
Surgical resection is a primary option for early-stage lung cancer (I-IIb) and specific locally advanced cases (T3N1).
Adjuvant chemotherapy and trimodality therapy are crucial for resectable stages II and IIIa, and limited N2 disease, respectively.

Purpose:

To outline current treatment strategies for lung cancer based on tumor stage and characteristics.
To highlight the role of surgery, chemotherapy, radiotherapy, and combined-modality approaches.
To discuss management of non-resectable disease and small cell lung cancer.

Summary:

Surgical treatment is recommended for clinical stage I to IIb and T3N1 lung cancer.
Adjuvant chemotherapy is indicated for stage II and IIIa, while trimodality therapy is used for limited N2 disease, offering a 20-40% five-year survival rate.
Definitive radiochemotherapy is the standard for non-resectable disease, with secondary resection considered in select cases. Personalized medicine offers new hope for patients with specific genetic alterations.

Impact:

Treatment decisions for lung cancer are complex, requiring individualized plans based on staging and patient factors.
While systemic chemotherapy and targeted therapies have limitations in unselected populations, personalized treatment strategies are improving outcomes.
Advances in multimodal therapies and personalized medicine are critical for improving survival rates in lung cancer patients.